[Cost-effectiveness of newborn screening for sickle cell anemia]

Castilla I, Valcárcel-Nazco C, Vallejo-Torres L, Cela E, Posada M, DulínÍñiguez E, Espada M, Rausell D, Mar J, Arrospide A, Serrano-Aguilar P
Record ID 32018013062
Spanish
Original Title: Análisis coste-efectividad del cribado neonatal de la enfermedad de células falciformes
Authors' objectives: To determine the efficiency of incorporating the early detection of sickle cell disease to neonatal screening programs already implemented in Spanish regions.
Authors' results and conclusions: RESULTS: Given the estimated birth prevalence in Spain (1:5591), there is a difference in effectiveness of 0.00005 LYGs per infant that favors HbS screening if a time horizon of 10 years is considered. By keeping costs per screened newborn at or below 1 €, neonatal screening for HbS saves costs for the same period. Screening is still efficient, for a willingness to pay of € 30,000 / LYG, if costs per screened newborn are below 2.5 €, incurring a global additional cost of 1.27 € per screened newborn, and obtaining an ICER of € 24,495.72 / LYG (€ 25,343.37 / QALY). CONCLUSIONS: Given the estimated birth prevalence of sickle cell disease in Spain, neonatal screening of this disease is cost-effective for a time horizon of 10 years and setting a willingness to pay of € 30,000 / QALY if the cost per screened newborn does not exceed 2.5 €. The uncertainty surrounding this decision is quite high, being the probability of the screening to be cost-effective not higher than 50% in any of the scenarios assessed.
Authors' methods: A discrete event simulation model has been developed that compares two alternatives: implementing newborn screening for sickle cell disease in a given population that already has a neonatal screening program; or continuing with the clinical detection of this pathology. The model follows the newborns for 10 years, reflecting the impact of preventive treatments that can be established through early detection. The perspective of the analysis was that of the National Health System, taking into account the direct healthcare costs, expressed as 2013 euros. The effectiveness of the intervention was measured by using life expectancy and health related quality of life. Both the costs and effectiveness were discounted at 3%. We performed a probabilistic sensitivity analysis using 2nd order Monte Carlo simulations, which allowed the calculation of acceptability curves and the expected value of perfect information.
Details
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Spain
MeSH Terms
  • Anemia, Sickle Cell
  • Neonatal Screening
  • Cost-Effectiveness Analysis
Keywords
  • Neonatal screening
  • Cystic fibrosis
  • Economic evaluation
Contact
Organisation Name: Canary Health Service
Contact Address: Dirección del Servicio. Servicio Canario de la Salud, Camino Candelaria 44, 1ª planta, 38109 El Rosario, Santa Cruz de Tenerife
Contact Name: sescs@sescs.es
Contact Email: sescs@sescs.es
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.